All Industry Insight articles – Page 50
-
News$1.7b acquisition to develop rare haematology therapy
When CTI BioPharma is acquired by Swedish Orphan Biovitrum AB (Sobi), the companies intend to advance an oral kinase inhibitor treatment for a rare haematological disease.
-
NewsLaunching Revvity: a scientific solutions company powering innovation from discovery to cure
Leveraging innovation across life sciences, Revvity focuses on transformation to revolutionise next generation scientific breakthroughs that solve the world’s greatest health challenges.
-
NewsSandoz to boost biosimilar development with manufacturing expansion
€25m funding is intended to unite a cutting-edge biotech lab and analytical expertise at Sandoz's German biosimilar manufacturing site.
-
NewsEMA to review CTIS transparency rules
Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency.
-
NewsDigital transformation to drive biomanufacturing market
According to a market report, digital transformation is becoming an essential part of biopharma manufacturing.
-
NewsFDA releases draft guidance for decentralised clinical trials
Recommendations on the conduct of remote clinical trial visits are included in new US Food and Drug Administration (FDA) draft guidance.
-
NewsAstellas to accelerate ocular disease treatments with $5.9 billion acquisition
A $5.9 billion acquisition of biotech Iveric Bio by Astellas is set to accelerate development of treatments for blinding retinal diseases.
-
NewsBristol Myers Squibb boosts CAR T therapy manufacturing capabilities
Securing in-house viral vector production capabilities in the US is set to help Bristol Myers Squibb manufacture its two CAR T-cell therapies.
-
NewsGlobal research consortium to help address antimicrobial resistance
Researchers in the UK, South Africa, Uganda and Brazil have formed the Centres for Antimicrobial Optimisation Network (CAMO-Net) to optimise antimicrobial use globally.
-
NewsPharma responds to proposed EU pharmaceutical legislation reform
Industry bodies EPFIA and the Alliance for Regenerative Medicine and law firm Pinsent Masons have responded to the recent proposed revision of the EU pharmaceutical legislation.
-
NewsBristol Myers Squibb appoints new CEO
Bristol Myers Squibb’s leadership team is set to reshuffle, with Christopher Boerner becoming it’s new CEO in late 2023.
-
NewsModerna’s mRNA vaccine manufacturing centre begins construction
Moderna achieves another milestone in its UK government partnership, with the start of construction of its mRNA vaccine manufacturing centre.
-
NewsBoehringer Ingelheim invests €350m in new biotech R&D facility
The new €350 million biotechnology R&D centre is Boehringer Ingelheim’s largest single investment in Germany to date.
-
NewsElectronic smart packaging market to value nearly $3b in 2033
While there is a keen interest in smart packaging worldwide, adopting these solutions at scale is challenging, a report has asserted.
-
NewsEli Lilly promises additional $1.6b manufacturing investment
A total $3.7 billion investment at LEAP Innovation Park in the US is Eli Lilly and Company’s largest manufacturing investment at a single location in its history.
-
NewsGSK to acquire BELLUS for £1.6 billion
A novel P2X3 antagonist is set to advance GSK's respiratory pipeline as part of its planned £1.6 billion acquisition of BELLUS Health.
-
NewsMerck to develop mAb through $10.8b acquisition
Through a $10.8 billion acquisition, Merck has agreed to buy Prometheus Biosciences to advance development of a novel monoclonal antibody for immune conditions.
-
ArticleTurning the TIDE: oligonucleotide development trends
Discover what is driving the oligonucleotide therapeutics sector as scientists navigate challenges such as financing and success-to-market.
-
NewsINTERPHEX 2023 – experience science through commercialisation
From development to distribution, leading global event Interphex 2023 (April 25-27 New York, US) takes you through all stages of the pharma product lifecycle.
-
NewsBiogen to develop amyloid beta-targeting antibody platform
The next-generation of anti- amyloid beta therapeutics could be advanced by Biogen exercising the option to develop Denali’s antibody programme.